Compare IVDA & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVDA | DRMA |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | 32 | 8 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.5M |
| IPO Year | N/A | N/A |
| Metric | IVDA | DRMA |
|---|---|---|
| Price | $0.28 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 863.5K | ★ 1.8M |
| Earning Date | 04-14-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $340.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.59 |
| 52 Week High | $3.13 | $7.33 |
| Indicator | IVDA | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 36.10 | 52.25 |
| Support Level | $0.27 | $0.63 |
| Resistance Level | $0.34 | $2.29 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 7.25 | 45.21 |
Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.